Neptra

RSS

florfenicol / terbinafine hydrochloride / mometasone furoate

Authorised
This medicine is authorised for use in the European Union.

Overview

Neptra is a veterinary medicine used to treat dogs with short lived or recurrent ear infections (otitis externa) caused by two organisms: Staphylococcus pseudintermedius (a bacterium) and Malassezia pachydermatitis (a yeast). Neptra contains three active substances: florfenicol, terbinafine and mometasone.

This EPAR was last updated on 28/04/2020

Authorisation details

Product details
Name
Neptra
Agency product number
EMEA/V/C/004735
Active substance
  • florfenicol
  • Terbinafine hydrochloride
  • Mometasone furoate
International non-proprietary name (INN) or common name
florfenicol / terbinafine hydrochloride / mometasone furoate
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QS02CA91
Publication details
Marketing-authorisation holder
Bayer Animal Health GmbH
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
10/12/2019
Contact address
51368 Leverkusen
Germany

Product information

24/04/2020 Neptra - EMEA/V/C/004735 - IB/0001

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Otologicals

  • Corticosteroids and antiinfectives in combination

Therapeutic indication

For the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis).

Assessment history

How useful was this page?

Add your rating
Average
1 rating